As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...
AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...